DLA PIPER LLP (US)

Lobbying for BIOHAVEN PHARMACEUTICALS, INC. · A biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Connecticut · House · Senate · $60,000.00 income · posted Apr 20, 2026

Lobbying activity 1

Health Issues

Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.